Cargando…
Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India
BACKGROUND: Miltefosine unresponsive and relapse cases of visceral leishmaniasis (VL) are increasingly being reported. However, there has been no laboratory confirmed reports of miltefosine resistance in VL. Here, we report two laboratory confirmed cases of VL from India. METHODS: Two patients with...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282768/ https://www.ncbi.nlm.nih.gov/pubmed/28137296 http://dx.doi.org/10.1186/s13071-017-1969-z |
_version_ | 1782503388831809536 |
---|---|
author | Srivastava, Saumya Mishra, Jyotsna Gupta, Anil Kumar Singh, Amit Shankar, Prem Singh, Sarman |
author_facet | Srivastava, Saumya Mishra, Jyotsna Gupta, Anil Kumar Singh, Amit Shankar, Prem Singh, Sarman |
author_sort | Srivastava, Saumya |
collection | PubMed |
description | BACKGROUND: Miltefosine unresponsive and relapse cases of visceral leishmaniasis (VL) are increasingly being reported. However, there has been no laboratory confirmed reports of miltefosine resistance in VL. Here, we report two laboratory confirmed cases of VL from India. METHODS: Two patients with VL were referred to us with suspected VL. The first patient was a native of the VL endemic state of Bihar, but residing in Delhi, a VL non-endemic area. He was treated with broad-spectrum antibiotics and antipyretics but was unresponsive to treatment. The second patient was from Jharkhand state in eastern India (adjoining Bihar), another endemic state for VL. He was refractory to anti-leishmanial treatment, which included administration of miltefosine. Following investigation, both patients were serologically positive for VL, and blood buffy coat from both patients grew Leishmania donovani. The isolates derived from both cases were characterized for their drug susceptibility, genetically characterised, and SNPs typed for LdMT and LdROS gene expression. Both patients were successfully treated with amphotericin B. RESULTS: The in vitro drug susceptibility assays carried out on both isolates showed good IC(50) values to amphotericin B (0.1 ± 0.0004 μg/ml and 0.07 ± 0.0019 μg/ml). One isolate was refractory to Sb(III) with an IC(50) of > 200 μM while the second isolate was sensitive to Sb(III) with an IC(50) of 36.70 ± 3.2 μM. However, in both the isolates, IC(50) against miltefosine was more than 10-fold higher (> 100 μM) than the standard strain DD8 (6.8 ± 0.1181 μM). Furthermore, genetic analyses demonstrated single nucleotide polymorphisms (SNPs) ((354)Tyr↔Phe and (1078)Phe↔Tyr) in the LdMT gene of the parasites. CONCLUSIONS: Here, we document two laboratory confirmed cases of miltefosine resistant VL from India. Our finding highlights the urgent need to establish control measures to prevent the spread of these strains. We also propose that LdMT gene mutation analysis could be used as a molecular marker of miltefosine resistance in L. donovani. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13071-017-1969-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5282768 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-52827682017-02-03 Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India Srivastava, Saumya Mishra, Jyotsna Gupta, Anil Kumar Singh, Amit Shankar, Prem Singh, Sarman Parasit Vectors Research BACKGROUND: Miltefosine unresponsive and relapse cases of visceral leishmaniasis (VL) are increasingly being reported. However, there has been no laboratory confirmed reports of miltefosine resistance in VL. Here, we report two laboratory confirmed cases of VL from India. METHODS: Two patients with VL were referred to us with suspected VL. The first patient was a native of the VL endemic state of Bihar, but residing in Delhi, a VL non-endemic area. He was treated with broad-spectrum antibiotics and antipyretics but was unresponsive to treatment. The second patient was from Jharkhand state in eastern India (adjoining Bihar), another endemic state for VL. He was refractory to anti-leishmanial treatment, which included administration of miltefosine. Following investigation, both patients were serologically positive for VL, and blood buffy coat from both patients grew Leishmania donovani. The isolates derived from both cases were characterized for their drug susceptibility, genetically characterised, and SNPs typed for LdMT and LdROS gene expression. Both patients were successfully treated with amphotericin B. RESULTS: The in vitro drug susceptibility assays carried out on both isolates showed good IC(50) values to amphotericin B (0.1 ± 0.0004 μg/ml and 0.07 ± 0.0019 μg/ml). One isolate was refractory to Sb(III) with an IC(50) of > 200 μM while the second isolate was sensitive to Sb(III) with an IC(50) of 36.70 ± 3.2 μM. However, in both the isolates, IC(50) against miltefosine was more than 10-fold higher (> 100 μM) than the standard strain DD8 (6.8 ± 0.1181 μM). Furthermore, genetic analyses demonstrated single nucleotide polymorphisms (SNPs) ((354)Tyr↔Phe and (1078)Phe↔Tyr) in the LdMT gene of the parasites. CONCLUSIONS: Here, we document two laboratory confirmed cases of miltefosine resistant VL from India. Our finding highlights the urgent need to establish control measures to prevent the spread of these strains. We also propose that LdMT gene mutation analysis could be used as a molecular marker of miltefosine resistance in L. donovani. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13071-017-1969-z) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-31 /pmc/articles/PMC5282768/ /pubmed/28137296 http://dx.doi.org/10.1186/s13071-017-1969-z Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Srivastava, Saumya Mishra, Jyotsna Gupta, Anil Kumar Singh, Amit Shankar, Prem Singh, Sarman Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India |
title | Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India |
title_full | Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India |
title_fullStr | Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India |
title_full_unstemmed | Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India |
title_short | Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India |
title_sort | laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from india |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282768/ https://www.ncbi.nlm.nih.gov/pubmed/28137296 http://dx.doi.org/10.1186/s13071-017-1969-z |
work_keys_str_mv | AT srivastavasaumya laboratoryconfirmedmiltefosineresistantcasesofvisceralleishmaniasisfromindia AT mishrajyotsna laboratoryconfirmedmiltefosineresistantcasesofvisceralleishmaniasisfromindia AT guptaanilkumar laboratoryconfirmedmiltefosineresistantcasesofvisceralleishmaniasisfromindia AT singhamit laboratoryconfirmedmiltefosineresistantcasesofvisceralleishmaniasisfromindia AT shankarprem laboratoryconfirmedmiltefosineresistantcasesofvisceralleishmaniasisfromindia AT singhsarman laboratoryconfirmedmiltefosineresistantcasesofvisceralleishmaniasisfromindia |